<DOC>
	<DOCNO>NCT01451723</DOCNO>
	<brief_summary>The hypothesis Polyphenon E protect brain cell patient Multiple Sclerosis . To test hypothesis go compare change n-Acetyl-Aspartate ( chemical reflect number neuron metabolism ) one year people MS treat Polyphenon E dose 400mg twice day people MS treat match sugar pill .</brief_summary>
	<brief_title>Safety Neuroprotective Effects Polyphenon E MS ; Phase II</brief_title>
	<detailed_description>This double blind placebo control trial Polyphenon E treatment MS . The primary outcome change NAA level one year . Secondary outcome change brain atrophy one year . As exploratory outcome correlate change NAA level free Plasma level EGCG 8 hour morning dose . Exploratory outcome include disability progression EDSS , MS functional composite component cognitive test battery .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neuroprotective Agents</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>Diagnosis MS McDonald criterion Relapsingremitting MS secondary progressive MS Stable therapy Copaxone , Rebif , Betaseron Avonex 30 mcg least six month EDSS Score less equal 7.0 Ages 1860 . Participants must normal organ marrow function define : 1 . Leukocytes ≥3,000/µL 2 . Absolute neutrophil count ≥1,500/µL 3 . Platelets ≥100,000/µL 4 . Total bilirubin ≤local upper limit normal 5 . AST ( SGOT ) ≤local upper limit normal 6 . ALT ( SGPT ) ≤local upper limit normal 7 . Creatinine ≤local upper limit normal MS relapse within 30 day prior enrollment A primary progressive form MS . Previous treatment prior study entry follow : complete radiation ablation bone marrow antiCD4 antibody treatment ( Campath ) time ; mitoxantrone , cyclophosphamide , Natalizumab immunomodulatory immunosuppressant therapy except DMT 's included inclusion criterion methylprednisone relapse within prior nine month . History renal liver disease . Consumption green tea supplement contain green tea tea extract within 30 day prior enrollment . Participants may participate clinical trial involve investigational agent study , within six month prior enrol study . History allergic reaction attribute compound similar chemical biologic composition Polyphenon E , tea , inactive ingredient present active placebo capsule , include gelatin . History allergic reaction gadolinium condition contraindicate MRI . Uncontrolled , clinicallyrelevant active illness ( aside MS ) include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Any condition would make subject , opinion investigator , unsuitable study Inability complete baseline MRI scan Pregnant woman Any underlying predisposition gastrointestinal bleeding ( peptic ulcer disease , gastritis , diverticulitis , colitis , hemorrhoid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Polyphenon E</keyword>
	<keyword>Green tea</keyword>
	<keyword>EGCG</keyword>
	<keyword>Epigallocatechin-galleate</keyword>
	<keyword>Placebo</keyword>
	<keyword>Randomized control trial</keyword>
</DOC>